How to buy Sana Biotechnology Inc stock (Sana Biotechnology Inc)

Sana Biotechnology, a company that develops platforms to replace or repair cells in our bodies, wrapped an upsized IPO at $588 million.

Morgan Stanley, Goldman Sachs Group, JPMorgan and BofA Securities were the bookrunners for the deal.

Our top picks for where to buy Sana Biotechnology stock

Buy Sana Biotechnology Inc stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sana Biotechnology Inc stock price (NASDAQ: SANA)

Use our graph to track the performance of SANA stocks over time.

Sana Biotechnology Inc shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$1.70
52-week range	$1.55 - $12.00
50-day moving average more info button	$2.86
200-day moving average more info button	$5.71
Wall St. target price	$9.40
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.40

Is it a good time to buy Sana Biotechnology Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sana Biotechnology Inc price performance over time

Historical closes compared with the close of $1.75 from 2024-12-24

1 week (2024-12-20)	6.06%
1 month (2024-11-27)	-31.37%
3 months (2024-09-27)	-59.11%
6 months (2024-06-27)	-67.59%

1 year (2023-12-27)	-59.02%
2 years (2022-12-27)	-45.14%
3 years (2021-12-27)	15.35
5 years (2019-12-23)	N/A

Sana Biotechnology Inc financials

Gross profit TTM	$0
Return on assets TTM	-31.15%
Return on equity TTM	-92.9%
Profit margin	0%
Book value	$1.31
Market Capitalization more info button	$390.7 million

TTM: trailing 12 months

Sana Biotechnology Inc share dividends

We're not expecting Sana Biotechnology Inc to pay a dividend over the next 12 months.

You may also wish to consider:

Sana Biotechnology Inc share price volatility

Over the last 12 months, Sana Biotechnology Inc's shares have ranged in value from as little as $1.55 up to $12. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sana Biotechnology Inc's is 1.442. This would suggest that Sana Biotechnology Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Sana Biotechnology Inc's beta into context you can compare it against those of similar companies.

• Editas Medicine (EDIT.US): 2.006
• Intellia Therapeutics (NTLA.US): 1.806
• Pacific Biosciences of California (PACB.US): 2.009

Sana Biotechnology Inc overview

Sana Biotechnology, Inc. , a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.

Frequently asked questions

What percentage of Sana Biotechnology Inc is owned by insiders or institutions?
Currently 8.633% of Sana Biotechnology Inc shares are held by insiders and 92.456% by institutions. How many people work for Sana Biotechnology Inc?
Latest data suggests 328 work at Sana Biotechnology Inc. When does the fiscal year end for Sana Biotechnology Inc?
Sana Biotechnology Inc's fiscal year ends in December. Where is Sana Biotechnology Inc based?
Sana Biotechnology Inc's address is: 188 East Blaine Street, Seattle, WA, United States, 98102 What is Sana Biotechnology Inc's ISIN number?
Sana Biotechnology Inc's international securities identification number is: US7995661045